Shilpa Medicare Limited

Shilpa Pharma Lifesciences Limited

Rafiuddin Dr

Vimal Kumar Shrawat

Vinod Kumar Singh

Prashant Purohit

Akshay Kant Chaturvedi

Akshaykant Chaturvedi

Nagnnath Kokare

Ananta Naga Kanaka Durga Reddy Guntaka

The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof. The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).

Crystalline bortezomib process

The present invention provides process for preparation of Fingolimod hydrochloride (I).  Fingolimod hydrochloride (I) as Form-&#x3b2; obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including multiple sclerosis.

Process for the preparation of fingolimod and its salts

The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2&#x3b8;&#xb0; peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40&#xb1;0.20 2&#x3b8;&#xb0;, DSC isotherm comprising the endothermic peaks ranging between 213 to 217&#xb0; C. (Peak &#x2212;1) and 225 to 235&#xb0; C. (Peak &#x2212;2) and IR absorption characteristic peaks at approximately 3278 cm, 1948 cm, 1871 cm, 1632 cm, 1164 cm, 1024 cm, 940 cmand 742 cmuseful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Crystalline erlotinib hydrochloride process

The present invention provides a non-solvated amorphous form of (2&#x3b1;,5&#x3b2;,7&#x3b2;,10&#x3b2;,13&#x3b1;)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I), and process for preparation thereof. The present application also provides a non-solvated amorphous form of (2&#x3b1;,5&#x3b2;,7&#x3b2;,10&#x3b2;,13&#x3b1;)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) having an XRPD pattern as per FIG., and IR spectrum as per FIG.and is useful as an active pharmaceutical in a pharmaceutical composition comprising thereof and has anti-cancer activity.

Process for preparing amorphous cabazitaxel

The present invention relates to crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide (I) designated as Form-SV and process for preparation thereof.  The invention further relates to pharmaceutical compositions comprising crystalline Form-SV or non-crystalline form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, useful in the treatment of cancer.

Growing community of inventors

Raichur, India

Rafiuddin Dr